Darren Cunningham CEO dcunningham@inflectionbio.com Presentation by Darren Cunningham CEO dcunningham@inflectionbio.com

Overview 1 in 3 will get cancer – many will not survive *** Our mission develop groundbreaking new treatments for those suffering with cancer

Business Model Value Inflection: 10-15 YEAR DEVELOPMENT LEAD DISC TARGET HITS LEAD PRE-CLIN IND PHASE 1 PHASE 2 PHASE 3 APP LAUNCH LEAD PRE-CLINICAL IND PACKAGE EARLY CLINICAL LICENSE IN PARTNER/ EXIT/IPO Value Inflection: 4 – 5 YEAR DEVELOPMENT

Phase I Value Creation Potential Phase I Oncology Exits $100m - >$300m

Collaboration with CNIO - June 2013 Spanish National Cancer Research Centre

Secure Partner after Phase I Pipeline – Targeted Therapeutics TARGET RESEARCH PRE-CLIN IND PHASE I NSCLC Secure Partner after Phase I IBL-300s (PIM/PI3K/mTOR) OTHER K-RAS TUMOURS B-CELL LYMPHOMAS IBL-202 (PIM/PI3K) MULTIPLE MYELOMA B-CELL LYMPHOMAS IBL-100s (Pan-PIM) HAEM MALIGNANCIES Secure Partner at IND Comprising first-in-class agents protected by composition of matter patents

PIM Kinase a driver of resistance in AKT/PI3K PIM expression dramatically elevated by PI3K/AKT pathway inhibition PIM mediates feedback loop driving acquired resistance to a number of treatment modalities. Underpins rationale for co-targeting PI3K and PIM; huge clinical opportunity

Lung cancer leading cause of cancer death (1.6m ww) IBL-300s – Targeting Molecular Subsets in NSCLC(Stage IV) Lung cancer leading cause of cancer death (1.6m ww) - NSCLC ~80% = $10bn market by 2020 De novo PI3k activation Mutant K-Ras EGFR TKI Resistant Squamous cc – PIK3CA/ PTEN mutations ~30% PIM and PI3K inhibitors act synergistically in vitro and in vivo PIM mediates PI3K/AKT resistance NSCLC - K-Ras mutated in 15-30% Downstream activation include PI3K/AKT/mTOR PIM inhibition shuts down growth in mutant K-Ras NSCLC cell lines NSCLC - EGFR mutations in ~10% de novo Cancer recurs (~12mo) with ~10% due to PI3K activation PIM elevated in EGFR TKI resistant lines Role for PI3K and PIM co-targeting in NSCLC Rationale for IBL-300s

Research Collaboration Network Network spanning US, EU, Australia NSCLC, pancreatic, ovarian, multiple myeloma, DLBCL, MCL, CLL, neuroblastoma, breast cancer, mechanistic

ONCOLOGY ADVISORY PANEL Leadership MANAGEMENT ONCOLOGY ADVISORY PANEL Darren Cunningham CEO 15 year record in licensing, M&A, IP, fundraising, IR Amarin, Elan, PWC B. Comm, M. Acc, FCA Dr. Michael O’Neill Director R&D 22 year drug discovery and development Eli Lilly, Almirall, Merck BA Psychology, PhD Dr. Martin Page 30+ years experience in oncology R&D Previous VP, Global Head of Oncology Res. J&J Roles with OSI Pharma, Oxford Glycosciences, and Glaxo-Wellcome Prof. Josep Tabernero Director, Vall d’Hebron Institute of Oncology Led clinical development of PI3K pathway inhibitors ESMO Executive Board Prof. Funda Meric-Bernstam Professor of Surgical Oncology; and Chair Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center

Corporate profile Incorporated 2012 Headquartered in Dublin, with base in London 2 full time employees Internship program, 3 in 2015 PhD in TCD via Innovation Partnership 6 board members; panel of international scientific advisors 6 CROs (UK, France, China, India) >10 research collaborations (US, Ireland, UK, Germany, Sweden, Australia) ~€2.2m raised to date (EI, VC and privates)

Thank you Darren Cunningham dcunningham@inflectionbio.com